Consequently, ALDH1A1 targeting can be important in an anticancer treatment, e.g., in acute myeloid leukemia [32], ovarian cancer [33], and triple-negative breast cancer [34]. This evidence concerns the gene ALDH1A1 and ovarian carcinoma.